Transcriptome Analysis Identifies LINC00152 as a Biomarker of Early Relapse and Mortality in Acute Lymphoblastic Leukemia

• Main Authors: Diego Alberto Bárcenas-López, Juan Carlos Núñez-Enríquez, Alfredo Hidalgo-Miranda, Fredy Omar Beltrán-Anaya, Didier Ismael May-Hau, Elva Jiménez-Hernández, Vilma Carolina Bekker-Méndez, Janet Flores-Lujano, Aurora Medina-Sansón, Edna Liliana Tamez-Gómez, Víctor Hugo López-García, José Ramón Lara-Ramos, Nora Nancy Núñez-Villegas, José Gabriel Peñaloza-González, Luz Victoria Flores-Villegas, Raquel Amador-Sánchez, Rosa Martha Espinosa-Elizondo, Jorge Alfonso Martín-Trejo, Martha Margarita Velázquez-Aviña, Laura Elizabeth Merino-Pasaye, María Luisa Pérez-Saldívar, David Aldebarán Duarte-Rodríguez, José Refugio Torres-Nava, Beatriz Cortés-Herrera, Karina Anastacia Solís-Labastida, Ana Itamar González-Ávila, Jessica Denisse Santillán-Juárez, Alejandra Jimena García-Velázquez, Haydee Rosas-Vargas, Minerva Mata-Rocha, Omar Alejandro Sepúlveda-Robles, Juan Manuel Mejía-Aranguré, Silvia Jiménez-Morales
• Format: Article
• Language: English
• Published: MDPI AG 2020-03-01
• Series: Genes
• Subjects: acute lymphoblastic leukemia; long noncoding rna; <i>linc00152</i>; <i>linc001013</i>; early relapse; microarray expression analysis
• Online Access: https://www.mdpi.com/2073-4425/11/3/302

Evidence showing the role of long non-coding RNAs (lncRNAs) in leukemogenesis have emerged in the last decade. It has been proposed that these genes can be used as diagnosis and/or prognosis biomarkers in childhood acute lymphoblastic leukemia (ALL). To know if lncRNAs are associated with early relapse and early mortality, a microarray-based gene expression analysis in children with B-lineage ALL (B-ALL) was conducted. Cox regression analyses were performed. Hazard ratios (HR) and 95% confidence intervals (95% CI) were calculated. <i>LINC00152</i> and <i>LINC01013</i> were among the most differentially expressed genes in patients with early relapse and early mortality. For <i>LINC00152</i> high expression, the risks of relapse and death were HR: 4.16 (95% CI: 1.46&#8722;11.86) and HR: 1.99 (95% CI: 0.66&#8722;6.02), respectively; for <i>LINC01013</i> low expression, the risks of relapse and death were HR: 3.03 (95% CI: 1.14&#8722;8.05) and HR: 6.87 (95% CI: 1.50&#8722;31.48), respectively. These results were adjusted by NCI risk criteria and chemotherapy regimen. The lncRNA&#8722;mRNA co-expression analysis showed that <i>LINC00152</i> potentially regulates genes involved in cell substrate adhesion and peptidyl&#8722;tyrosine autophosphorylation biological processes. The results of the present study point out that <i>LINC00152</i> could be a potential biomarker of relapse in children with B-ALL.